COMP <GO>
GILD vs UNH // REVENUE GROWTH (YOY)
Gilead Sciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GILD 7
— UNH 7
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $167.47 (-1.68%) • MKT CAP: $211.27B
revenue-growth
2.40%
LAST: $404.44 (+1.00%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 88.31% | -9.51 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 12.38% | +8.62 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 15.3x | +5.73 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 6.25% | -1.65 | UNH | /fcf-yield <GO> |
| Operating Margin | 34.00% | 5.32% | +28.68 | GILD | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 3.53% | +25.37 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 2.40% | 3.33% | -0.93 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 2.29% | -0.34 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 3.09 | +2.78 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.4 | 55.1 | +13.30 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | GILD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 17.7x | +4.66 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $211.27B | $359.43B | -$148.17B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | UNH REV | GILD GROSS % | UNH GROSS % | GILD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $447.57B | 78.8% | 88.7% | $9.46B | $16.07B |
| FY 2024 | $28.75B | $400.28B | 78.3% | 88.3% | $10.30B | $20.70B |
| FY 2023 | $27.12B | $371.62B | — | 89.6% | $6.79B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
UNH // BETA 0.33